SIBO Treatment Protocol: A Functional Medicine Approach to Small Intestinal Bacterial Overgrowth

At a Glance

In my clinical practice, SIBO is one of the most consistently under-diagnosed conditions I encounter in patients presenting with medically unexplained bloating, fatigue, and malabsorption. What frequently passes as “irritable bowel syndrome” or vague dyspepsia often has a bacterial — and therefore treatable — root cause. More significantly, in patients with complex chronic conditions like Lyme disease, post-COVID syndrome, or mold illness, untreated SIBO perpetuates systemic inflammation and undermines every other therapeutic intervention.

This guide consolidates the diagnostic framework, treatment protocols, and relapse-prevention strategies I use clinically — drawing on current gastroenterology evidence alongside the functional medicine lens necessary to address the underlying drivers.

What Is SIBO and Why It Matters Systemically

The healthy small intestine maintains a bacterial density of fewer than 10³ colony-forming units per milliliter (CFU/mL). SIBO is defined by a count exceeding 10⁵ CFU/mL, though functional practitioners now recognize that even lower-level dysbiosis can be clinically significant when the wrong species dominate.

The small intestine is not designed to tolerate fermentation. When bacteria proliferate here, they:

• Compete for nutrients — particularly carbohydrates, B12, and fat-soluble vitamins (A, D, E, K)
• Generate fermentation gases — hydrogen and methane causing bloating, altered motility, and pain
• Damage the brush border — reducing digestive enzyme activity and triggering intestinal permeability (“leaky gut”)
• Drive systemic inflammation — lipopolysaccharide (LPS) from gram-negative bacteria translocates into circulation, activating innate immune responses

In patients with Lyme disease or post-COVID, this LPS-driven immune activation compounds an already dysregulated inflammatory milieu. I have seen SIBO treatment lead to meaningful improvements in brain fog, joint pain, and fatigue in these patients — not because SIBO causes their primary condition, but because it amplifies it.

Three Clinical Phenotypes

Understanding which gas type dominates guides treatment selection:

Hydrogen-dominant SIBO presents with diarrhea or alternating bowel habits, rapid bloating, and cramping. This is the most common type and responds well to rifaximin monotherapy or herbal antimicrobials.

Methane-dominant SIBO (Intestinal Methanogen Overgrowth / IMO) presents with constipation, slower transit, and significant bloating. Methanogens are archaea, not bacteria — they consume hydrogen and produce methane. This phenotype requires combination therapy (rifaximin + neomycin, or allicin + other antimicrobials).

Hydrogen sulfide SIBO — now detectable with newer multi-gas breath testing — presents with sulfur-smelling gas, diarrhea, and sometimes neurological symptoms. This type is underrecognized and requires specific interventions including bismuth and molybdenum.

Diagnosing SIBO: Breath Testing Essentials

Lactulose vs. Glucose Breath Test

The lactulose breath test (LBT) is my preferred diagnostic tool. Lactulose is not absorbed in the small intestine, so it serves as bacterial substrate throughout the entire small bowel. Hydrogen and/or methane in expired air are measured at 20-minute intervals for 90–120 minutes.

Positive criteria (North American Consensus):

• Hydrogen rise ≥ 20 ppm above baseline within 90 minutes
• Methane ≥ 10 ppm at any point (for IMO)
• Combined hydrogen + methane ≥ 15 ppm (some practitioners use this threshold)

The glucose breath test is more specific but less sensitive — glucose is absorbed in the proximal small bowel, so it misses mid- and distal SIBO. It has a role when false-positive rates with lactulose are a concern (e.g., accelerated transit).

Organic Acid Testing (OAT)

In patients who cannot tolerate breath testing preparation, the organic acid test (OAT) provides indirect evidence of microbial metabolites — arabinitol for yeast overgrowth, and various bacterial metabolites that suggest dysbiosis. While not diagnostic for SIBO specifically, an elevated D-arabinitol in context of symptoms warrants treatment consideration.

Clinical Diagnosis When Testing Is Unavailable

An empirical trial of antimicrobial therapy is acceptable when breath testing access is limited. A positive response — reduced bloating, improved transit, clearer cognition — constitutes reasonable clinical confirmation.

The SIBO Treatment Protocol

Phase 1: Antimicrobial Eradication (Weeks 1–4)

Pharmaceutical Options:

Rifaximin (Xifaxan) is a minimally absorbed rifamycin antibiotic that acts locally in the gut. Standard dosing is 550 mg three times daily for 14 days for hydrogen-dominant SIBO. It achieves bacterial load reduction without significant systemic antibiotic side effects or disruption of the colonic microbiome — a meaningful advantage over systemic antibiotics.

For methane-dominant SIBO/IMO, rifaximin is combined with neomycin 500 mg twice daily for 14 days. This combination targets both bacterial hydrogen producers and the archaea that consume hydrogen to produce methane. A 2021 Digestive Diseases and Sciences study demonstrated significantly higher methane clearance rates with dual therapy compared to rifaximin alone.

Herbal Antimicrobial Options:

For patients preferring non-pharmaceutical approaches, or when rifaximin access is limited, herbal antimicrobial protocols show comparable efficacy. A landmark 2014 study by Chedid et al. in Global Advances in Health and Medicine found herbal therapy as effective as rifaximin for normalizing breath tests.

Effective herbal protocols include:

I typically run herbal protocols for 4 weeks given slower onset compared to rifaximin. I do not combine all herbs simultaneously — rotating or pairing 2–3 based on gas type is more targeted and better tolerated.

Phase 2: Motility and Structural Support (Throughout)

One of the most overlooked SIBO interventions is restoring the migrating motor complex (MMC) — the housekeeping wave that clears residual bacteria from the small intestine between meals. Impaired MMC is a primary driver of SIBO recurrence.

Prokinetics during and after treatment:

• Low-dose naltrexone (LDN) 1.5–4.5 mg at night supports MMC and has anti-inflammatory effects on the gut wall
• Iberogast (botanical prokinetic blend) 20 drops three times daily with meals
• Ginger extract 250–500 mg before meals
• Prucalopride (prescription 5-HT4 agonist) for severe motility impairment, particularly post-infectious or post-surgical SIBO

Prokinetics should continue for 3–6 months post-treatment to prevent recolonization.

Phase 3: Dietary Modification

Diet during SIBO treatment is a tool to reduce fermentation load — not a cure. I advise:

Low FODMAP diet during the eradication phase reduces bacterial substrate and symptom burden. This is a temporary strategy (4–6 weeks maximum during active treatment); long-term FODMAP restriction worsens microbiome diversity and is counterproductive.

Specific Carbohydrate Diet (SCD) or Bi-Phasic Diet are alternatives with a stronger evidence base for longer-term gut healing. The Bi-Phasic Diet by Dr. Nirala Jacobi specifically pairs dietary phase with treatment phase.

Elemental diet — pre-digested amino acid and fat formula providing complete nutrition while starving bacteria — achieves 80%+ SIBO clearance rates in 2–3 weeks according to gastroenterology data. It is highly effective but challenging to tolerate. I reserve it for severe, refractory, or post-surgical SIBO.

What to avoid during treatment:

• Fiber supplements (feed bacteria)
• Probiotic supplements (controversial — may worsen hydrogen production in active SIBO)
• Alcohol and simple sugars

Addressing Root Causes — The Key to Preventing Relapse

SIBO has a 40–60% relapse rate at 9 months if underlying drivers are not addressed. This is the primary reason conventional gastroenterology manages but rarely resolves SIBO: rifaximin without root-cause work produces temporary relief.

Common Root Causes

Hypochlorhydria: Low stomach acid allows bacteria that should be destroyed in the stomach to pass into the small intestine. Contributing factors: proton pump inhibitors (PPIs), chronic stress, H. pylori, aging. Betaine HCl supplementation or assessment of gastric acid adequacy is essential.

Impaired MMC / Motility disorders: Post-infectious neuropathy (particularly post-Clostridioides difficile, post-COVID, or post-Campylobacter), diabetic gastroparesis, hypothyroidism, and opioid use all impair the MMC. Addressing the underlying cause is non-negotiable.

Structural abnormalities: Adhesions from prior abdominal surgery, Crohn’s-related strictures, or ileocecal valve dysfunction can physically trap bacteria in the small bowel. These require structural assessment and sometimes surgical consultation.

Immune dysfunction: SIBO is significantly more prevalent in patients with IgA deficiency, HIV, and chronic inflammatory conditions. In my practice, patients with chronic Lyme disease and post-COVID frequently have SIBO — the immune dysregulation impairs gut mucosal defense. Treating the primary immune condition is essential.

Dysbiosis-promoting medications: PPIs, repeated antibiotic courses, and opioids all predispose to SIBO. If these cannot be discontinued, enhanced prokinetic support is required.

Gut Repair After SIBO Eradication

Once bacterial overgrowth is cleared, the small intestine requires active repair:

Mucosal healing: L-glutamine 5 g twice daily supports enterocyte tight junctions and reduces intestinal permeability. Zinc carnosine 75 mg daily accelerates mucosal repair. BPC-157 (peptide) shows preclinical and emerging clinical evidence for gut mucosal healing — an area of active interest in my practice.

Reintroducing beneficial bacteria: Post-treatment, selective reintroduction of Lactobacillus rhamnosus, Bifidobacterium longum, and Saccharomyces boulardii helps reestablish colonization resistance. I wait 4–6 weeks post-antimicrobial therapy before introducing probiotics, and use colonic-targeted formulations.

Digestive enzyme support: Pancreatic enzyme replacement (lipase, protease, amylase) supports nutrient absorption during the recovery phase when brush border function remains impaired.

Bile acid support: TUDCA (tauroursodeoxycholic acid) 500 mg daily supports bile flow — important in patients with fat malabsorption or prior cholecystectomy where bile acid dysregulation may have contributed to SIBO.

SIBO in Complex Chronic Illness: Clinical Considerations

In patients with Lyme disease, the relationship between SIBO and infection is bidirectional. Antibiotic therapy — while necessary for Borrelia treatment — profoundly disrupts the small intestinal microbiome. I routinely screen for SIBO in patients who have received prolonged antibiotic courses, particularly those whose bloating, fatigue, and brain fog worsen during Lyme treatment.

Post-COVID SIBO is an emerging clinical pattern. ACE2 receptor expression in the gut, disruption of the gut microbiome by the SARS-CoV-2 infection itself, and post-infectious motility impairment all create fertile ground for bacterial overgrowth. The brain fog and fatigue of post-COVID syndrome can be meaningfully improved by addressing concurrent SIBO — an intervention that deserves systematic investigation.

Mold-related illness (CIRS) also correlates with SIBO, likely through mast cell activation, impaired secretory IgA, and altered gut motility. In these patients, SIBO treatment is a necessary component of the overall detoxification and recovery protocol.

Related Articles

• Gut-Brain Axis Healing: How Your Microbiome Drives Mental Health
• Biofilm Disruption: Why Infections Resist Treatment
• Functional Medicine Lab Testing: What to Order and Why
• Low-Dose Naltrexone (LDN): A Physician’s Protocol Guide
• BPC-157 for Gut Healing: Evidence and Protocol

References

1. Pimentel M, et al. “ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.” Am J Gastroenterol. 2020;115(2):165–178. PMID: 32022696
2. Chedid V, et al. “Herbal Therapy Is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth.” Glob Adv Health Med. 2014;3(3):16–24. PMID: 24891990
3. Rezaie A, et al. “Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus.” Am J Gastroenterol. 2017;112(5):775–784. PMID: 28323273
4. Low K, et al. “A Combination of Rifaximin and Neomycin Is Most Effective in Treating Irritable Bowel Syndrome Patients with Methane on Lactulose Breath Test.” J Clin Gastroenterol. 2010;44(8):547–550. PMID: 20216426
5. Ghoshal UC, et al. “Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy.” Gut Liver. 2017;11(2):196–208. PMID: 27840364
6. Gabrielli M, et al. “Rifaximin Dosing Regimens for Small Intestinal Bacterial Overgrowth: Meta-analysis.” Aliment Pharmacol Ther. 2009;29(10):1075–1082. PMID: 19222410
7. Sachdev AH, Pimentel M. “Gastrointestinal Bacterial Overgrowth: Pathogenesis and Clinical Significance.” Ther Adv Chronic Dis. 2013;4(5):223–231. PMID: 23997926